rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    QTTB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Q32 Bio at Jefferies Global Healthcare Conference: phase iii push
      15h agoInvesting.comQTTB
      Q32 Bio: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceQTTB
      Q32 bio CSO Shelia Violette sells $7,629 of company stock
      Oct 14Investing.comQTTB
      Q32 Bio CFO and president Lee Kalowski sells $10,824 in shares
      Oct 14Investing.comQTTB
      Q32 Bio CEO Jodie Morrison sells $26,798 in stock
      Oct 14Investing.comQTTB
      Oppenheimer reiterates Q32 Bio stock rating on durable trial data
      Oct 1Investing.comQTTB
      Why is Q32 Bio stock sliding today?
      Oct 1Investing.comQTTB
      Why is Q32 Bio stock surging today?
      Sep 30Investing.comQTTB
      Why is Q32 Bio stock surging today?
      Sep 29Investing.comQTTB
      Clear Street initiates Q32 Bio stock with buy rating on drug potential
      Sep 28Investing.comQTTB
      Jefferies initiates Q32 Bio stock coverage with buy rating on alopecia potential
      Sep 28Investing.comQTTB
      Jefferies Initiates Q32 Bio at Buy With $29 Price Target
      Sep 28Yahoo FinanceQTTB
      Q32 Bio: Durable Hair Regrowth Remains The Goal (NASDAQ:QTTB)

      QTTB stock outlook: bempikibart may deliver lasting alopecia areata hair regrowth; financing reduces near-term risk.

      Sep 26Seeking AlphaQTTB
      Cantor Fitzgerald reiterates Q32 Bio stock rating on hair loss data
      Sep 16Investing.comQTTB
      Q32 Bio at cantor healthcare conference: bempikibart gains ground
      Sep 9Investing.comQTTB
      Q32 Bio at Wells Fargo conference: bempikibart eyes safer alopecia edge
      Sep 8Investing.comQTTBWFC
      Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround

      The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

      Sep 7Yahoo FinanceQTTB
      Q32 Bio CEO Jodie Morrison sells $163,033 in company stock
      Aug 27Investing.comQTTB
      Q32 Bio: A Deep Dive (NASDAQ:QTTB)
      Aug 27Seeking AlphaQTTB
      Q32 Bio: The Efficacy Is Modest, The Valuation Is Not (NASDAQ:QTTB)
      Aug 24Seeking AlphaQTTB
      Morgan Stanley initiates Q32 Bio stock at Overweight on drug potential
      Aug 24Investing.comQTTB

      This is the newest page. Registered accounts read further back.